SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51828The global CRISPR and cas genes market size was valued at USD 1.5 billion in 202Frank Sully18/11/2021
51827JMP Securities Stick to Their Buy Rating for Crispr Therapeutics AGInvesting.cFrank Sully-8/10/2021
51826Well the market is yawning on Exact's interest in NVTA. If it's surmisiA.J. Mullen-8/9/2021
51825Invitae, NVTA, is up 10% post-market on news of an offer from Exact Sciences, EXA.J. Mullen-8/6/2021
51824Theranos' patients will be allowed to testify against Holmes, wsj.com I didnA.J. Mullen-8/4/2021
51823AI Transforms Genomic Data into Actionable Insights Frank Sully18/2/2021
51822CRISPER Therapeutics EPS beats by $5.59, beats on revenue CRSP is up about 7.5%Frank Sully-7/29/2021
51821CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 FinaFrank Sully-7/29/2021
51820AI breakthrough will 'transform' biology By Paul RinconScience editor, Frank Sully-7/22/2021
51819What´s hot in NASH these days? Recent data by Akero Therapeutics (AKRO) loodr_elis-7/21/2021
51818Pacific Biosciences, PacB, the company that differentiated itself from Illumina A.J. Mullen-7/20/2021
51817A Chinese firm may be interested. Art Art Bechhoefer-7/17/2021
51816"But Geoffrey Porges, an analyst at SVB Leerink, said he expects AstraZenecJamesK-7/17/2021
51815We'll have to see the details. It says non inferior to ESA in NDD. ESA isn&#JamesK-7/17/2021
51814I see. I had misunderstood. Agree the attorneys will be rubbing their hands anA.J. Mullen-7/16/2021
51813Ashley -- I was only pointing out that my training, especially in research desigArt Bechhoefer-7/16/2021
51812The knowledge that GSK's Deprodustat and Akebia's Vadadustat both look pArt Bechhoefer-7/16/2021
51811I had no idea. Thanks.A.J. Mullen-7/16/2021
51810The drug seemed so promising for [US] NDD patients. It might have extended theirDewDiligence_on_SI17/16/2021
51809Art, I don't think comparing qualifications is a good way to settle disputesA.J. Mullen17/16/2021
51808AJ -- You noted that "I think it's right they confer before making theiArt Bechhoefer-7/16/2021
51807Here's one report of the FDA FGEN meeting yesterday, fiercepharma.comA.J. Mullen17/16/2021
51806FGEN's press release. Nothing of value in it. investor.fibrogen.com Stock mJamesK-7/15/2021
51805We disagree on several points and agree on one. I've already said I was impA.J. Mullen-7/15/2021
51804One panel member suggested a trial with poor responders to EPO. Not a big targeA.J. Mullen-7/15/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News